Review
doi: 10.1182/blood-2017-08-784066.
Epub 2017 Oct 19.
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Affiliations
- PMID: 29051180
- DOI: 10.1182/blood-2017-08-784066
Item in Clipboard
Review
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Blood.
.
Free article
Abstract
In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therapy-related AML and AML with myelodysplasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33. Promising results also emerged for the BCL-2 inhibitor venetoclax combined with low-intensity therapy in older patients unfit for intensive chemotherapy. This quintet of new drugs is likely to reshape the therapeutic landscape of AML.
© 2017 by The American Society of Hematology.
Similar articles
-
How I treat acute myeloid leukemia in the era of new drugs.Blood. 2020 Jan 9;135(2):85-96. doi: 10.1182/blood.2019001239. Blood. 2020. PMID: 31765470
-
Venetoclax-based therapies for acute myeloid leukemia.Best Pract Res Clin Haematol. 2019 Jun;32(2):145-153. doi: 10.1016/j.beha.2019.05.008. Epub 2019 May 24. Best Pract Res Clin Haematol. 2019. PMID: 31203996 Free PMC article. Review.
-
Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?Best Pract Res Clin Haematol. 2017 Dec;30(4):312-316. doi: 10.1016/j.beha.2017.09.006. Epub 2017 Sep 22. Best Pract Res Clin Haematol. 2017. PMID: 29156201 Review.
-
New drugs creating new challenges in acute myeloid leukemia.Genes Chromosomes Cancer. 2019 Dec;58(12):903-914. doi: 10.1002/gcc.22750. Epub 2019 Apr 11. Genes Chromosomes Cancer. 2019. PMID: 30861214 Review.
-
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.Leuk Res. 2018 Oct;73:58-66. doi: 10.1016/j.leukres.2018.09.001. Epub 2018 Sep 8. Leuk Res. 2018. PMID: 30223250 Review.
Cited by
-
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML.Nat Rev Cancer. 2020 Mar;20(3):158-173. doi: 10.1038/s41568-019-0230-9. Epub 2020 Jan 6. Nat Rev Cancer. 2020. PMID: 31907378 Review.
-
Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells.Oncotarget. 2018 Dec 28;9(102):37777-37789. doi: 10.18632/oncotarget.26540. eCollection 2018 Dec 28. Oncotarget. 2018. PMID: 30701031 Free PMC article.
-
Clinical Implications of Inflammation in Acute Myeloid Leukemia.Front Oncol. 2021 Feb 22;11:623952. doi: 10.3389/fonc.2021.623952. eCollection 2021. Front Oncol. 2021. PMID: 33692956 Free PMC article. Review.
-
Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies.Cancers (Basel). 2019 Dec 25;12(1):69. doi: 10.3390/cancers12010069. Cancers (Basel). 2019. PMID: 31881776 Free PMC article. Review.
-
Identification of STAB1 in Multiple Datasets as a Prognostic Factor for Cytogenetically Normal AML: Mechanism and Drug Indications.Mol Ther Nucleic Acids. 2019 Dec 6;18:476-484. doi: 10.1016/j.omtn.2019.09.014. Epub 2019 Sep 23. Mol Ther Nucleic Acids. 2019. PMID: 31670197 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
